Clinical Trials Logo
  1. Home
  2. Lymphoma, Non-Hodgkin's
  3. NCT00363636

A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin's Clinical Trial

Official title:
A Phase III, Randomized, Double-Blind Study of Galiximab in Combination With Rituximab Compared With Rituximab in Combination With Placebo for the Treatment of Subjects With Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma

Clinical Trial Summary

This is a Phase III, multicenter, global, clinical study of an investigational drug called galiximab in combination with an approved drug called rituximab in subjects with follicular NHL.

The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with placebo) in subjects with follicular NHL. Safety and pharmacokinetics (PK) of galiximab and rituximab will also be evaluated.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00363636
Study type Interventional
Source Biogen
Contact
Status Terminated
Phase Phase 3
Start date September 2006
Completion date April 2010
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00594308 - In-Vivo Activated T-Cell Depletion to Prevent GVHD N/A
Terminated NCT02518750 - Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Phase 2
Completed NCT01733238 - Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 2
Terminated NCT00384150 - Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) Phase 3
Terminated NCT00141700 - Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma Phase 2
Terminated NCT00143884 - Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood Phase 2
Completed NCT02750670 - Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Phase 2
Terminated NCT02473523 - Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia N/A
Completed NCT00413036 - A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma Phase 2
Completed NCT00161590 - Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Phase 1
Terminated NCT00651443 - Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma Phase 1
Recruiting NCT04756726 - Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma Phase 1/Phase 2
Terminated NCT00395967 - AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone Phase 2
Completed NCT00143871 - Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma Phase 2